CNS (CNS) Stock Analysis
Verdict: AVOID
Premium P/E of 22x faces earnings misses and 6 analyst sell ratings, offset by a 4.0% dividend yield and robust 31% operating margins.
Investment score: 37/100
The model recommends avoiding CNS stock due to a rich valuation (P/E 22.05x vs peer median 11.34x), three consecutive quarterly EPS misses, and persistent sell sentiment from institutional analysts.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| MAIN | 11.34 | 1.63 | 7.47 | 17.00 | — | 0.65 |
| HLNE | 13.56 | 4.00 | 5.81 | 9.26 | — | 0.32 |
| OTF | 8.17 | 0.65 | 3.56 | 17.86 | — | 0.27 |
| FHI | 10.42 | 3.26 | 2.22 | 7.53 | — | 0.21 |
| AB | 10.50 | 2.66 | 9.62 | 9.62 | — | 0.91 |